CN110028480A - 布雷菲德菌素a的4,7-位拼合美法仑类氮芥衍生物及其制备方法和用途 - Google Patents
布雷菲德菌素a的4,7-位拼合美法仑类氮芥衍生物及其制备方法和用途 Download PDFInfo
- Publication number
- CN110028480A CN110028480A CN201810042469.XA CN201810042469A CN110028480A CN 110028480 A CN110028480 A CN 110028480A CN 201810042469 A CN201810042469 A CN 201810042469A CN 110028480 A CN110028480 A CN 110028480A
- Authority
- CN
- China
- Prior art keywords
- brefeldin
- melphalan
- pharmaceutically acceptable
- preparation
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- -1 melphalan class nitrogen mustard derivatives Chemical class 0.000 title claims description 17
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical group O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 claims abstract description 38
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical class OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims abstract description 11
- 150000003839 salts Chemical group 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960001924 melphalan Drugs 0.000 claims description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical class OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000006555 catalytic reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- YHYUQHQOUXSXQE-ZDUSSCGKSA-N methyl (2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 YHYUQHQOUXSXQE-ZDUSSCGKSA-N 0.000 claims 1
- 239000012624 DNA alkylating agent Substances 0.000 abstract description 3
- 229940126161 DNA alkylating agent Drugs 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000006667 mitochondrial pathway Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- DZBCEUTUWOWUDY-ZETCQYMHSA-N Ascochitine Chemical compound OC1=C(C(O)=O)C(=O)C=C2C(C)=C([C@@H](C)CC)OC=C21 DZBCEUTUWOWUDY-ZETCQYMHSA-N 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000985535 Penicillium decumbens Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001679 anti-nematodal effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- DZBCEUTUWOWUDY-UHFFFAOYSA-N ascochitine Natural products OC1=C(C(O)=O)C(=O)C=C2C(C)=C(C(C)CC)OC=C21 DZBCEUTUWOWUDY-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及天然药物及药物化学领域,布雷菲德菌素A的4,7‑位拼合美法仑类氮芥衍生物的制备方法和用途。具体涉及这些在布雷菲德菌素A的4‑OH及7‑OH位点引入DNA烷化剂美法仑衍生物的制备方法及其在制备抗肿瘤药物中的应用。本发明所述的布雷菲德菌素A的4,7‑位拼合美法仑类氮芥衍生物及其药学上可接受的盐结构如通式I所示,其中,n如权利要求书和说明书中所述。
Description
技术领域
本发明属于天然药物及药物化学领域,涉及布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其制备方法和用途,具体涉及布雷菲德菌素A的4-OH及7-OH位点进行修饰的衍生物,涉及这些在4-OH及7-OH位点被DNA烷化剂美法仑衍生物取代的布雷菲德菌素A衍生物及其制备方法和在制备抗肿瘤药物中的应用。
背景技术
布雷菲德菌素A(brefeldin A,BFA)是一种子囊菌属(Ascomycetes)的次级代谢产物,属于大环内酯型抗生素,也称为斜卧菌素或壳二孢素。它于1958年,由Singleton等人从Penicillium decumbens的发酵液中分离得到。布雷菲德菌素A,晶体呈棱状,白色,不溶于石油醚、氯仿、水,易溶于乙酸乙酯、丙酮和甲醇。药理研究表明,布雷菲德菌素A具有抗肿瘤、抗病毒、抗真菌、抗线虫和抗有丝分裂等药理活性,其中抗肿瘤活性尤为显著。NCI的研究表明布雷菲德菌素A可以选择性抑制并杀死人肿瘤细胞。大环内酯抗生素布雷菲德菌素A作为一种内质网应激剂可以诱导多种肿瘤细胞发生凋亡,抑制细胞增殖等多种途径抑制并杀死肿瘤细胞,其中包括人宫颈癌细胞、前列腺癌细胞、慢性淋巴白血病细胞和滤泡淋巴瘤细胞等对多种肿瘤细胞均有抑制作用。研究表明布雷菲德菌素A通过激活线粒体和死亡受体途径以及抑制黏着斑激酶调节的细胞侵袭来诱导凋亡。例如,布雷菲德菌素A可以通过激活线粒体通路和capase-8、Bid依赖型通路诱导卵巢癌细胞发生凋亡。布雷菲德菌素A的凋亡效应可能是由活性氧的产生以及谷胱甘肽的消耗来调节的,这种调节会导致凋亡相关caspase途径的激活。另外,布雷菲德菌素A可以抑制由胎牛血清诱导的OVCAR-3细胞的黏附和转移。这种效应是通过抑制黏着斑激酶依赖的细胞内相关成分的激活来完成的。布雷菲德菌素A通过线粒体通路导致caspase-3、6的激活进而诱导内质网应激调节的凋亡。随着对布雷菲德菌素A药理作用研究的深入,布雷菲德菌素A引起了国内外科学家的极大兴趣,开展了对布雷菲德菌素A衍生物的合成工作。目的是获得活性更好、毒性更低、性质更稳定的抗肿瘤候选化合物。与提取分离、作用机制方面的报道相比,关于布雷菲德菌素A结构修饰与改造、衍生物合成等药物化学方面的报道较少。
氮芥类药物,也称为DNA烷化剂,属于细胞毒类药物,其作用机制是在体内能形成缺电子的高度活泼中间体或其他具有活泼的亲电性基团的化合物,进而与生物大分子发生共价不可逆结合,使DNA分子丧失活性或发生断裂。这类药物在临床上被广泛使用,但它的毒副作用比较大,对细胞作用缺乏特异性,而且随着近年来肿瘤耐药的发生,治疗效果并不理想,因此,对氮芥类药物进行化学修饰,改善其疗效有着很重要的价值。
发明内容
本发明所要解决的技术问题是寻找抗肿瘤活性好的布雷菲德菌素A拼合美法仑衍生物,即布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物,并进一步提供包含该衍生物的药物组合物,所述的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物或其组合物具有抗肿瘤活性。
为解决上述技术问题,本发明提供如下技术方案:
通式I为所示布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐:
其中,n为1-12的整数。
优选地,n为1-6的整数。
更优选地,n为2。
本发明通式I的衍生物可用下列方法制备得到:
美法仑(2)与甲醇在SOCl2存在的条件下,加热回流反应得到美法仑甲酯(3),然后(3)在DMAP催化的条件下与二酸酐反应得美法仑甲酯羧酸衍生物(4)。
布雷菲德菌素A(1)与2当量美法仑甲酯羧酸衍生物(4)在EDCI/DMAP条件下室温反应得到化合物(5)。
本发明还提供了一种药物组合物,包含通式I所示的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐和药学上可接受的赋形剂。
本发明的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐或其药物组合物可以与临床上可接受的载体制备成临床上可接受的制剂,所述的制剂为片剂、颗粒剂、胶囊剂等。
本发明以布雷菲德菌素A为先导化合物,利用拼合原理,选择活性性较好的美法仑衍生物,将其通过连接基团连接到其分子结构的4-OH及7-OH位上,设计并合成了通式为I的布雷菲德菌素A拼合美法仑衍生物。拼合后的化合物具有较好的药学活性。
具体实施方式
实施例1
取布雷菲德菌素A1(32mg,0.08mmol),溶于二氯甲烷(2.5ml)中,依次加入美法仑甲酯丁酸(68mg,0.16mmol)、EDCI(29mg,0.15mmol)和催化量的DMAP,室温搅拌反应,TCL监测反应进程,24h后终止反应。将反应液倾入20ml冰水混合物中,二氯甲烷萃取(30ml×3),饱和食盐水溶液洗涤,无水硫酸钠干燥,回收二氯甲烷,经硅胶柱(石油醚:乙酸乙酯=2:1),分离,得黄色油状物5-1,收率24%。HR-MS(ESI,M+H)m/z:calcd for C43H51Cl2N5O7H:1081.3661,found 1081.3552.1H NMR(400MHz,DMSO-d6):δ(ppm)7.23(1H,dd,J=15.8,3.1Hz,C3-H),7.03(4H,d,J=8.5Hz,Ar-H),6.64(4H,d,J=8.4Hz,Ar-H),5.75(1H,m,C11-H),5.64(1H,dd,J=15.8,1.5Hz,C2-H),5.17-5.24(2H,m,C4,C10-H),4.98(1H,m,C7-H),4.73(1H,m,C15-H),4.33-4.40(2H,m,-NH),3.69(16H,m,-NCH2CH2Cl),3.57-3.58(6H,s,-OCH3),0.74-2.89(29H,m,-COCH2CH2CO-,-ArCH2CHNCO-,C5,2C6,2C8,C9,2C12,2C13,2C14-H,CH3).13CNMR(100MHz,DMSO-d6):δ(ppm)172.6,172.6,172.2,171.7,171.3,171.3,165.4,148.6,145.4,145.4,136.4,131.1,130.6,130.6,130.6,130.6,125.6,125.6,117.7,112.1,112.1,112.1,112.1,76.3,75.2,71.6,54.4,54.4,52.6,52.6,52.6,52.6,52.2,52.2,49.6,43.0,41.6,41.6,41.6,41.6,41.6,41.6,37.8,36.4,36.4,33.9,31.8,30.0,30.0,29.5,29.2,21.1.
药理试验
实验设备与试剂
实验方法
细胞抑制活性实验方法
细胞在37℃、5%CO2饱和湿度的培养箱中常规培养。培养液为含10%热灭活胎牛血清,青霉素100U/mL和链霉素100U/mL的RPMI1640细胞培养基。48h更换培养液,细胞贴壁后,用0.25%胰蛋白酶消化传代。实验用细胞均处于对数生长期,台盼蓝拒染法表明细胞活力>95%。
取处于对数生长期状态良好的细胞一瓶,加入消化液(0.125%胰蛋白酶+0.01%EDTA)消化,计数2~4×104cell/mL,制成细胞悬液接种于96孔板上,100μL/孔,置恒温CO2培养箱中培养24小时。换液,加入受试药物,100μL/孔,培养72小时。将CCK-8加入96孔板中,50μL/孔,培养箱中孵育4小时。吸去上清液,加DMSO,200μL/孔,平板摇床上震荡10分钟。受试物考察3个浓度(0.25μM,0.5μM,1μM),用酶联免疫监测仪在波长为450nm处测定每孔的吸光度,分别计算各浓度下的细胞抑制率。
抑制率计算方法:
药敏孔相对OD值=药敏孔绝对OD值﹣空白对照孔绝对OD值
实验结果
表1实施例对5种人类癌细胞株和1种正常肝细胞株抗增殖活性的IC50值(μM)
药理试验证明,本发明的布雷菲德菌素A衍生物对正常细胞株的毒性远小于肿瘤细胞株,具有选择性,可以进一步用于制备抗肿瘤药物。
Claims (9)
1.通式I所示的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐:
其中,n为1-12的整数。
2.权利要求1所述的通式I所示的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐:
其中,n为1-6的整数。
3.权利要求1或2所述的通式I所示的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐:
其中,n为2,即
4.一种药物组合物,其中含有治疗有效量的权利要求1-3任何一项所述的通式I所示的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐和药学上可接受的载体。
5.一种药物制剂,其特征在于,包含权利要求1-3任何一项所述的通式I所示的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐或权利要求4所述的药物组合物。
6.如权利要求1所述的通式I所示的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐的制备方法,其特征在于:
美法仑(2)与甲醇在SOCl2存在的条件下,加热回流反应得到美法仑甲酯(3),然后(3)在DMAP催化的条件下与二酸酐反应得美法仑甲酯羧酸衍生物(4);
布雷菲德菌素A(1)与2当量美法仑甲酯羧酸衍生物(4)在EDCI/DMAP条件下室温反应得到化合物(5);
7.权利要求1-3任何一项所述的通式I所示的布雷菲德菌素A的4,7-位拼合美法仑类氮芥衍生物及其药学上可接受的盐在制备治疗肿瘤疾病的药物中的应用。
8.权利要求4所述的药物组合物或权利要求5所述的药物制剂在制备治疗肿瘤疾病的药物中的应用。
9.如权利要求7或8所述的应用,其特征在于,所述的肿瘤为白血病、前列腺癌或肝癌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810026936X | 2018-01-11 | ||
CN201810026936 | 2018-01-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110028480A true CN110028480A (zh) | 2019-07-19 |
CN110028480B CN110028480B (zh) | 2021-01-29 |
Family
ID=67234853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810042469.XA Active CN110028480B (zh) | 2018-01-11 | 2018-01-17 | 布雷菲德菌素a的4,7-位拼合美法仑类氮芥衍生物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110028480B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116535380A (zh) * | 2023-05-15 | 2023-08-04 | 沈阳药科大学 | 一类布雷菲德菌素a的异硫氰酸酯衍生物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103788053A (zh) * | 2012-10-30 | 2014-05-14 | 浙江工业大学 | 布雷菲德菌素a酯类衍生物及其制备与应用 |
CN106928209A (zh) * | 2017-03-10 | 2017-07-07 | 沈阳药科大学 | 布雷菲德菌素a衍生物及其制备方法和用途 |
-
2018
- 2018-01-17 CN CN201810042469.XA patent/CN110028480B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103788053A (zh) * | 2012-10-30 | 2014-05-14 | 浙江工业大学 | 布雷菲德菌素a酯类衍生物及其制备与应用 |
CN106928209A (zh) * | 2017-03-10 | 2017-07-07 | 沈阳药科大学 | 布雷菲德菌素a衍生物及其制备方法和用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116535380A (zh) * | 2023-05-15 | 2023-08-04 | 沈阳药科大学 | 一类布雷菲德菌素a的异硫氰酸酯衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110028480B (zh) | 2021-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110563703B (zh) | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 | |
CN104072493B (zh) | 一类含2-巯基苯并噻唑和三唑杂环的萘酰亚胺化合物,其制备方法及其应用 | |
CN103739616A (zh) | 含噻唑基雷帕霉素类衍生物及其应用 | |
CN107602557B (zh) | 一类氮芥类吴茱萸碱衍生物及其制备方法和用途 | |
CN107721975A (zh) | 具有抗肿瘤活性的brd4小分子抑制剂、合成方法及其应用 | |
CN109053841B (zh) | 6-双硫取代-2’-脱氧鸟苷类化合物及其制备方法和应用 | |
CN108467394B (zh) | 一类α-硫辛酸类H2S供体与吴茱萸碱拼合物及其制备方法和用途 | |
CN110028482B (zh) | 布雷菲德菌素a的4-位拼合美法仑类氮芥衍生物及其制备方法和用途 | |
CN110028480A (zh) | 布雷菲德菌素a的4,7-位拼合美法仑类氮芥衍生物及其制备方法和用途 | |
CN109912653B (zh) | 一种具有抗肿瘤活性的吩噻嗪类衍生物及其合成方法 | |
CN108191866B (zh) | 一类adt-oh类h2s供体与吴茱萸碱拼合物及其制备方法和用途 | |
CN110028477B (zh) | 一类布雷菲德菌素a的4-位拼合氮芥衍生物的制备方法和用途 | |
CN110028478B (zh) | 一类布雷菲德菌素a的4,7-位拼合氮芥衍生物的制备方法和用途 | |
CN106883277B (zh) | 一类具有抗肿瘤活性的呋咱类no供体型灯盏乙素衍生物及其制备方法和用途 | |
CN113773356B (zh) | 一种胡黄连苷ii衍生物及其制备方法和应用 | |
CN108690033B (zh) | 含黄酮类药物活性分子的荧光探针及其制备方法和应用 | |
CN113527391B (zh) | 一种梓醇衍生物及其制备方法和应用 | |
Wang et al. | Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of colorectal cancer | |
CN110028481B (zh) | 布雷菲德菌素a的7-位拼合美法仑类氮芥衍生物的制备方法和用途 | |
EP3542796A1 (en) | Compound having anti-cancer effect, and preparation method therefor and use thereof | |
CN113004268B (zh) | 一种抑制肿瘤细胞生长的噻唑化合物及其用途 | |
EP3543228A1 (en) | Compound having anticancer activity, and preparation method and application thereof | |
CN112979638B (zh) | 一种噻唑化合物及其用途 | |
CN110028479B (zh) | 一类布雷菲德菌素a的7-位拼合氮芥衍生物的制备方法和用途 | |
WO2019056376A1 (zh) | 酸敏感的吉非替尼-氟硼二吡咯衍生物及其制备方法和在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |